RESEARCH - Anti-CCP and AKAs in patients with idiopathic inflammatory myopathy

[Guest guest]

Rheumatology Advance Access originally published online on April 22, 2009

Rheumatology 2009 48(6):676-679; doi:10.1093/rheumatology/kep065

Anti-cyclic citrullinated peptide and anti-keratin antibodies in

patients with idiopathic inflammatory myopathy

Moisés Labrador-Horrillo1, Mª Angeles ez2, Albert

Selva-O’Callaghan1, Francisco Delgado2, Xavier Martínez-Gómez3,

Ernesto Trallero-Araguás1, -2 and Miquel

Vilardell-Tarrés1

1Internal Medicine Department, Vall d'Hebron General Hospital,

2Immunology Department, Hospital de la Santa Creu i Sant Pau and

3Preventive Medicine and Epidemiology Department, Vall d'Hebron

General Hospital, Universitat Autonòma de Barcelona, Barcelona, Spain.

Abstract

Objective. To investigate the prevalence of anti-cyclic citrullinated

peptide (anti-CCP) and anti-keratin antibodies (AKAs) in a cohort of

patients with idiopathic inflammatory myopathy.

Methods. In a cross-sectional study, we determined the presence of

anti-CCP and AKAs by ELISA and IIF, respectively, in a cohort of 90

consecutive patients with idiopathic inflammatory myopathy.

Associations between anti-CCP and clinical manifestations or other

autoantibodies were determined with the chi-square and Mann–Whitney

U-tests. Radiographs of hands were retrospectively evaluated. Serum

autoantibody profile was determined in all patients.

Results. Twelve patients were positive to anti-CCP (13.3%); in eight

cases values were moderate–high. AKAs were not detected in any

patient. Comparison between patients positive and negative to anti-CCP

did not show clinical or biological differences. Arthritis joint

erosions or positive status to anti-synthetase antibodies were not

more frequent in patients with anti-CCP antibodies. Prevalence of RF

was the only variable significantly associated with the presence of

these antibodies (P = 0.043).

Conclusions. High titres of anti-CCP can occasionally be found in

patients with inflammatory myopathy. Therefore, a possible diagnosis

of RA should be considered with caution in these patients.

http://rheumatology.oxfordjournals.org/cgi/content/abstract/48/6/676?etoc

Not an MD